Welcome to our dedicated page for Calithera Biosciences news (Ticker: CALA), a resource for investors and traders seeking the latest updates and insights on Calithera Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Calithera Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Calithera Biosciences's position in the market.
Calithera Biosciences (CALA) reported its financial results for Q1 2021, showing a cash balance of $102.9 million as of March 31, 2021. The company is actively enrolling patients in critical clinical trials, including the KEAPSAKE trial for non-small cell lung cancer and a Phase 1b trial for cystic fibrosis treatment (CB-280). The firm anticipates interim data releases for both trials later this year. Total R&D expenses decreased to $15.3 million, while general and administrative costs rose to $5.4 million. The net loss for the quarter was $20.4 million.
Calithera Biosciences (CALA) will release its Q1 2021 financial results on May 6, 2021. A conference call hosted by management will take place the same day at 2:00 PM PT to discuss these results and recent corporate developments. Interested parties can access the press release and webcast via the company's website. Calithera specializes in developing targeted therapies to treat cancer, focusing on starving tumor cells and enhancing immune responses. Its commitment to advancing innovative therapeutics positions it as a key player in the biotechnology sector.
Calithera Biosciences (CALA) announced it will present final results from the CANTATA clinical study at the ASCO 2021 Annual Meeting. This study evaluated the efficacy of telaglenastat combined with cabozantinib versus placebo in patients with advanced renal cell carcinoma (RCC). Topline results revealed no improvement in progression-free survival (PFS). The presentation, led by Dr. Nizar M. Tannir, is set for June 7, 2021, during the Genitourinary Cancer session. Calithera aims to advance targeted therapies for cancer treatment.
Calithera Biosciences (CALA) announced its Q4 2020 financial results, reporting cash and investments of $115.2 million as of December 31, 2020. The company continues to advance key clinical trials, including the KEAPSAKE trial for telaglenastat in non-small cell lung cancer and a Phase 1b trial of CB-280 for cystic fibrosis. However, the CANTATA trial did not meet its primary endpoint. Research and development expenses decreased to $71.0 million in 2020. Calithera's net loss was $22.6 million for Q4 2020 and $90.1 million for the full year.
Calithera Biosciences (CALA) announced that it will release its fourth quarter 2020 financial results on March 16, 2021. A conference call will follow at 2:00 p.m. PT to discuss these results and recent corporate highlights. The announcement showcases Calithera's focus on developing novel therapies for cancer treatment and emphasizes its commitment to advancing a pipeline of oral therapeutics. Key financial data and business developments will likely be addressed during the call, accompanied by a live audio webcast available on the company’s website.
Calithera Biosciences, a clinical-stage biotechnology company, will release its fourth quarter 2020 financial results on March 16, 2021. A conference call is scheduled for the same day at 2:00 PM PT / 5:00 PM ET to discuss these results and other corporate highlights. Investors can access the release and live webcast via the company's website. Calithera focuses on developing targeted therapies for cancer and other serious diseases, emphasizing the advancement of its oral therapeutics pipeline. The company is based in South San Francisco, California.
Calithera Biosciences announced that its founder and CEO, Susan Molineaux, Ph.D., will present at the H.C. Wainwright Virtual Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. EST. The presentation will be accessible for replay for 30 days on the company's website in the Investor Relations section. Calithera, based in South San Francisco, focuses on developing innovative small molecule drugs aimed at cancer and other serious diseases, enhancing treatment options for patients.
Calithera Biosciences (Nasdaq: CALA) announced that its founder and CEO, Susan Molineaux, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on February 26, 2021, at 1:40 p.m. ET. The session will be available via live webcast and can be replayed for up to 30 days on their website.
Calithera is focused on developing targeted therapies for cancer and life-threatening diseases, with a commitment to improving treatment options through innovative small molecule drugs.
Calithera Biosciences (Nasdaq: CALA) announced the presentation of preliminary data on the safety and efficacy of arginase inhibitor INCB001158, developed by Incyte Pharmaceuticals, at the ASCO 2021 Gastrointestinal Cancers Virtual Symposium from January 15-17, 2021. The Phase I/II trial focuses on patients with advanced biliary tract cancers, with a presentation available from January 15 at 5:00 a.m. PT. The study is led by Dr. Milind Javle from the University of Texas MD Anderson Cancer Center.
Calithera Biosciences (Nasdaq: CALA) announced that CEO Susan Molineaux will present at the H.C. Wainwright VIRTUAL BioConnect Conference on January 11, 2021. The presentation will be accessible via webcast for 30 days on their investor relations website. Calithera focuses on developing novel small molecule drugs targeting cancer and other serious diseases, emphasizing improving treatment options for patients. The company is committed to advancing its pipeline of therapies, although future clinical outcomes and approvals carry inherent risks and uncertainties.